Adamis Pharmaceuticals (NASDAQ: ADMP) is one of 104 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Adamis Pharmaceuticals to similar companies based on the strength of its analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Adamis Pharmaceuticals and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adamis Pharmaceuticals 0 0 3 0 3.00
Adamis Pharmaceuticals Competitors 871 3792 6768 180 2.54

Adamis Pharmaceuticals presently has a consensus price target of $10.00, indicating a potential upside of 146.91%. As a group, “Pharmaceuticals” companies have a potential upside of 23.93%. Given Adamis Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe Adamis Pharmaceuticals is more favorable than its rivals.

Profitability

This table compares Adamis Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Adamis Pharmaceuticals -143.15% -57.74% -42.37%
Adamis Pharmaceuticals Competitors -2,399.85% -67.97% -7.27%

Risk & Volatility

Adamis Pharmaceuticals has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Adamis Pharmaceuticals’ rivals have a beta of 36.93, indicating that their average share price is 3,593% more volatile than the S&P 500.

Valuation & Earnings

This table compares Adamis Pharmaceuticals and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Adamis Pharmaceuticals $6.47 million -$19.43 million -5.79
Adamis Pharmaceuticals Competitors $8.17 billion $1.09 billion 144.90

Adamis Pharmaceuticals’ rivals have higher revenue and earnings than Adamis Pharmaceuticals. Adamis Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

16.7% of Adamis Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.8% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 9.6% of Adamis Pharmaceuticals shares are owned by company insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Adamis Pharmaceuticals rivals beat Adamis Pharmaceuticals on 7 of the 12 factors compared.

Adamis Pharmaceuticals Company Profile

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

Receive News & Ratings for Adamis Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.